



## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.111

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

### Editorial

- 1595** IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab  
*Y Tanaka, E M Mola*

### Viewpoint

- 1598** Hyperuricaemia and gout: time for a new staging system?  
*N Dalbeth, L Stamp*

### Review

- 1601** The complement system in systemic lupus erythematosus: an update  
*J Leffler, A A Bengtsson, A M Blom*

### Clinical and epidemiological research

- 1607** Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study  
*M C Genovese, R Fleischmann, D Furst, N Janssen, J Carter, B Dasgupta, J Bryson, B Duncan, W Zhu, C Pitzalis, P Durez, K Kretzschmar*
- 1616** Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy  
*J S Smolen, M E Weinblatt, S Sheng, Y Zhuang, B Hsu*
- 1626** Sarilumab, a fully human monoclonal antibody against IL-6R $\alpha$  in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial  
*T W J Huizinga, R M Fleischmann, M Jasson, A R Radin, J van Adelsberg, S Fiore, X Huang, G D Yancopoulos, N Stahl, M C Genovese*
- 1635** The global burden attributable to low bone mineral density  
*L Sánchez-Riera, E Carnahan, T Vos, L Veerman, R Norman, S S Lim, D Hoy, E Smith, N Wilson, J M Nolla, J S Chen, M Macara, N Kamalaraj, Y Li, C Kok, C Santos-Hernández, L March*
- 1646** Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study  
*J-A Lin, C-C Liao, Y-J Lee, C-H Wu, W-Q Huang, T-L Chen*
- 1652** The longitudinal relationship between changes in body weight and changes in medial tibial cartilage, and pain among community-based adults with and without meniscal tears  
*A J Teichtahl, A E Wluka, Y Wang, B J Strauss, J Proietto, J B Dixon, G Jones, A Forbes, S Kouloyan-Ilic, J Martel-Pelletier, J-P Pelletier, F M Cicuttini*

- 1659** Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints  
*D Prieto-Alhambra, A Judge, M K Javaid, C Cooper, A Diez-Perez, N K Arden*
- 1665** Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial  
*A R Balanescu, E Feist, G Wolfram, I Davignon, M D Smith, M T Brown, C R West*
- 1673** Evaluation of the RABBIT Risk Score for serious infections  
*A Zink, B Manger, J Kaufmann, C Eisterhues, A Krause, J Listing, A Strangfeld*
- 1677** Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register  
*C A Scirè, M Lunt, T Marshall, D P M Symmons, S M M Verstappen*
- 1683** Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis  
*A W M Evers, E W M Verhoeven, H van Middendorp, F C G J Sweep, F W Kraaijaard, A R T Donders, A E Eijsbouts, A I M van Laarhoven, S J M de Brouwer, L Wirken, T R D J Radstake, P L C M van Riel*
- 1689** Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)  
*A Kavanaugh, I B McInnes, P Mease, G G Krueger, D Gladman, D van der Heijde, Y Zhou, J Lu, J H Leu, N Goldstein, A Beutler*
- 1695** What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort  
*K Takase, S C Horton, A Ganesha, S Das, A McHugh, P Emery, S Savic, M H Buch*

### MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

COPE COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

**Basic and translational research**

- 1700** Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?  
*M Manetti, I Rosa, A F Milia, S Guiducci, P Carmeliet, L Ibba-Manneschi, M Matucci-Cerinic*
- 1710** Augmented pain behavioural responses to intra-articular injection of nerve growth factor in two animal models of osteoarthritis  
*S Ashraf, P I Mapp, J Burston, A J Bennett, V Chapman, D A Walsh*
- 1719** Enhancement of the synthesis of n-3 PUFAs in *fat-1* transgenic mice inhibits mTORC1 signalling and delays surgically induced osteoarthritis in comparison with wild-type mice  
*M-j Huang, L Wang, D-d Jin, Z-m Zhang, T-y Chen, C-h Jia, Y Wang, X-c Zhen, B Huang, B Yan, Y-h Chen, S-f Li, J-c Yang, Y-f Dai, X-c Bai*
- 1728** A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints  
*L Mullen, G Adams, J Foster, S Vessillier, M Köster, H Hauser, L Layward, D Gould, Y Chernajovsky*
- 1737** Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout  
*A Chhana, K E Callon, M Dray, B Pool, D Naot, G D Gamble, B Coleman, G McCarthy, F M McQueen, J Cornish, N Dalbeth*
- 1742** Influence of the *IL17A* locus in giant cell arteritis susceptibility  
*A Márquez, J Hernández-Rodríguez, M C Cid, R Solans, S Castañeda, M E Fernández-Contreras, M Ramenol, I C Morado, J Narváez, C Gómez-Vaquero, V M Martínez-Taboada, N Ortega-Centeno, B Sopena, J Monfort, M J García-Villanueva, L Caminal-Montero, E de Miguel, R Blanco, Spanish GCA Consortium, O Palm, O Molberg, J Latus, N Braun, F Moosig, T Witte, L Beretta, A Santaniello, G Pazzola, L Boiardi, C Salvarani, M A González-Gay, J Martín*

**Letters**

- 1746** Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis  
*M C Turina, J Steper, N Yermenko, K Conrad, H Haibel, M Rudwaleit, D Baeten, D Poddubnyy*

- 1748** Neutral lateral fingertip-to-floor distance can be derived from height  
*S Ramiro, A van Tubergen, C Stolwijk, D van der Heijde, R Landewé*
- 1749** Investigation of a *PON1* gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis  
*R López-Mejías, F Genre, A Corrales, C González-Juanatey, B Uvilla, J Llorca, J A Miranda-Filloo, T Pina, R Blanco, S Castañeda, J Martín, M A González-Gay*
- 1750** Genotyping of immune-related genetic variants identifies *TYK2* as a novel associated locus for idiopathic inflammatory myopathies  
*M Jani, J Massey, L R Wedderburn, J Vencovský, K Danko, I E Lundberg, L Padyukov, A Selva-O'Callaghan, T Radstake, H Platt, R B Warren, C E Griffiths, A Lee, P K Gregersen, F W Miller, W E Ollier, R G Cooper, H Chinoy, J A Lamb, and EUMYONET*

**Electronic pages**

- e54** Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?  
*R Fleischmann, Y Yazici*
- e55** Response to: 'Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?' by Fleishman and Yazici  
*M H Schiff, J S Jaffe, B Freundlich*
- e56** Comparison of *Tripterygium wilfordii* Hook F with methotrexate in the treatment of rheumatoid arthritis  
*D M Marcus*
- e57** Response to D.M. Marcus's comment on the TRIFRA study (comparison of *Tripterygium wilfordii* Hook F vs methotrexate in the treatment of active rheumatoid arthritis)  
*Q-w Lv, W Zhang, Q Shi, W-j Zheng, P E Lipsky, X Zhang*
- e58** HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?  
*T Ignatova, O Chernova, P Novikov, S Moiseev*
- e59** HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova *et al*  
*D Saadoun, P Cacoub*